Fortsat indgift af ritonavir bør vurderes med undersøgelse for virusbelastning på grund af muligheden for udvikling af resistens, som beskrevet i 4. 1.
The continuation of ritonavir therapy should be evaluated by viral load because of the possibility of the emergence of resistance as described under section 4.1 Therapeutic indications.